|
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). |
|
|
|
Consulting or Advisory Role - AstraZeneca; McKesson |
Research Funding - AbbVie (Inst); AstraZeneca (Inst); Biomarin (Inst); Medivation (Inst); Myriad Genetics (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Consulting or Advisory Role - Hanmi; Novartis; Spectrum Pharmaceuticals |
|
|
Honoraria - Amgen; AstraZeneca; Pfizer; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Pfizer; Pierre Fabre; Roche |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Pharmamar (Inst) |
|
|
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin |
Research Funding - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Myriad Genetics |
Patents, Royalties, Other Intellectual Property - Ambry Genetics (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Roche/Genentech |
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; celgene; Novartis |